Aurobindo Pharma Ltd (AUROPHARMA)

Motilal Oswal Rates Aurobindo Pharma as Neutral - 16 May, 2024

A recent report by Motilal Oswal has given a neutral rating to Aurobindo Pharma with a target price of Rs. 1180. While the company's biosimilar pipeline is expected to provide commercial benefit from FY26/FY27 onwards, limited upside from current levels led to the neutral rating.

US FDA Inspects Aurobindo Pharma's API Manufacturing Facility - 13 May, 2024

The US FDA inspected Unit-VII, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary of Aurobindo Pharma Ltd. The inspection closed with one procedural observation.

Aurobindo Pharma Expected to Breakout, Target of Rs 1250 - 09 May, 2024

Technical analysis suggests Aurobindo Pharma may reach a target of Rs 1250 within a month. It is recommended to buy at current levels with a stop loss of Rs 1097.

Aurobindo Pharma Shows Promising Technical Indicators - 08 May, 2024

Equity research analyst Deven Mehata suggests traders consider initiating positions in Aurobindo Pharma, leveraging the Bull Call Spread strategy to capitalize on potential upside movements. The stock exhibits strength with solid support near 1,120 levels and a minor resistance at 1177 levels. A breakthrough above this barrier could propel it towards the Fib Extension target of 1,200.

Aurobindo Pharma Receives Seven Observations from USFDA - 06 May, 2024

The US Food and Drug Administration conducted an inspection at Aurobindo Pharma's Unit II Rajasthan facility, concluding with seven procedural observations.

Aurobindo Pharma's Rajasthan Facility Concludes US FDA Audit With Observations - 04 May, 2024

Aurobindo Pharma's Rajasthan-based facility has concluded its US FDA audit with nine observations. However, the company reported a significant increase in consolidated net profit and revenue from operations for Q3 FY24.

Aurobindo Pharma Receives Tax Demand and US FDA Observations - 03 May, 2024

Aurobindo Pharma has received a tax demand of over Rs 13 crore from the GST authority and its Rajasthan unit has received seven procedural observations from the US FDA. The company intends to file an appeal against the tax demand. There is no material impact on its financials or operations due to the order. The stock ended 0.8% lower on May 3.

Aurobindo Pharma Subsidiary Acquires Joint Venture Shares - 02 May, 2024

Aurobindo Pharma's subsidiary, Aurogen South Africa, is set to acquire all shares held by other joint venture partners in Purple Bellflower, making it a wholly-owned subsidiary. HDFC Securities' Unmesh Sharma expects Aurobindo Pharma to benefit from the patent cliff and short supply of key drugs.

Aurobindo Pharma Leads in Active Drug Shortages in US Market - 30 Apr, 2024

Aurobindo Pharma, Sun Pharmaceutical Industries, and Gland Pharma are projected to make significant strides in the US market due to elevated levels of active drug shortages. Aurobindo Pharma leads with 36 products under shortage, followed by Sun Pharmaceutical Industries and Gland Pharma. Jeewani and Bagrecha recommend Aurobindo Pharma as the preferred choice among export-oriented generic manufacturers.

Aurobindo Pharma Stock Shows Strong Performance - 29 Apr, 2024

Aurobindo Pharma's stock has shown strong performance, with an 86.54% increase in the last year and a 1.79% increase on the NSE today. The company is also among several pharma stocks that have given a strong breakout.

Private Companies Hold 37% Stake in Aurobindo Pharma - 28 Apr, 2024

A significant proportion of Aurobindo Pharma Limited is owned by private companies, with the top five shareholders holding a majority stake. Institutional investors also have a fair amount of ownership, indicating credibility in the investment community. Insiders own a meaningful ₹101b stake in this ₹663b business, while the general public owns a 15% stake.

Investec Maintains Buy Rating on Aurobindo Pharma - 25 Apr, 2024

Investment bank Investec has maintained a buy rating on Aurobindo Pharma with a target price of Rs 1350. The bank expects earnings momentum to sustain as the company is a big beneficiary of the US generic macro improvement, and a ramp up in PenG production is likely to aid earnings momentum.

Aurobindo Pharma Sees Increase in Revenue and Profit; ICICI Sets Target Price - 17 Apr, 2024

Aurobindo Pharma sees a rise in revenue and net profit during Q3FY24. ICICI Prudential Mutual Fund acquires 3.60% stake. ICICI Securities sets target price of Rs 1,270 with potential 15% return.